Reported Earnings • Nov 29
First half 2026 earnings released: HK$0.009 loss per share (vs HK$0.012 profit in 1H 2025) First half 2026 results: HK$0.009 loss per share (down from HK$0.012 profit in 1H 2025). Revenue: HK$1.93b (down 6.4% from 1H 2025). Net loss: HK$10.3m (down 173% from profit in 1H 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Announcement • Nov 28
EC Healthcare Declares No Dividend for the Six Months Ended September 20, 2025 EC Healthcare declared no dividend for the six months ended September 20, 2025 (2024: 1.0 HK Cents). Announcement • Nov 17
EC Healthcare to Report First Half, 2026 Results on Nov 28, 2025 EC Healthcare announced that they will report first half, 2026 results on Nov 28, 2025 New Risk • Oct 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$746.7m (US$96.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (HK$746.7m market cap, or US$96.1m). New Risk • Aug 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Aug 04
Full year 2025 earnings released: HK$0.14 loss per share (vs HK$0.016 loss in FY 2024) Full year 2025 results: HK$0.14 loss per share (further deteriorated from HK$0.016 loss in FY 2024). Revenue: HK$4.14b (down 1.7% from FY 2024). Net loss: HK$167.2m (loss widened HK$148.2m from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Announcement • Jun 23
EC Healthcare Announces Appointment of Member of the Nomination Committee The board of directors of EC Healthcare announced that Mrs. Leung Yang, Shih Ti Marianne, a non-executive director of the Company and Mr. Ma Ching Nam, an independent non-executive director of the Company, have been appointed as the members of the nomination committee under the Company with effect from 23 June 2025. Reported Earnings • Jun 20
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: HK$0.14 loss per share (further deteriorated from HK$0.016 loss in FY 2024). Revenue: HK$4.20b (flat on FY 2024). Net loss: HK$167.2m (loss widened HK$148.2m from FY 2024). Revenue missed analyst estimates by 14%. Earnings per share (EPS) were also behind analyst expectations. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Announcement • Jun 19
EC Healthcare, Annual General Meeting, Aug 22, 2025 EC Healthcare, Annual General Meeting, Aug 22, 2025. Announcement • Jun 09
EC Healthcare to Report Fiscal Year 2025 Results on Jun 19, 2025 EC Healthcare announced that they will report fiscal year 2025 results on Jun 19, 2025 New Risk • May 21
New major risk - Revenue and earnings growth Earnings have declined by 47% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (HK$746.7m market cap, or US$95.4m). New Risk • Apr 07
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$687.4m (US$88.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (HK$687.4m market cap, or US$88.5m). New Risk • Jan 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (HK$711.1m market cap, or US$91.3m). New Risk • Jan 06
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$746.7m (US$96.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (HK$746.7m market cap, or US$96.1m). Upcoming Dividend • Dec 23
Upcoming dividend of HK$0.01 per share Eligible shareholders must have bought the stock before 30 December 2024. Payment date: 24 January 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 3.0%. Lower than top quartile of Hong Kong dividend payers (8.1%). Lower than average of industry peers (6.5%). Declared Dividend • Nov 30
Dividend of HK$0.01 announced Shareholders will receive a dividend of HK$0.01. Ex-date: 30th December 2024 Payment date: 24th January 2025 Dividend yield will be 1.4%, which is lower than the industry average of 5.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (4% cash payout ratio). The dividend has increased over the past 8 years. However, payments have been volatile during that time. Reported Earnings • Nov 29
First half 2025 earnings released: EPS: HK$0.012 (vs HK$0.006 in 1H 2024) First half 2025 results: EPS: HK$0.012 (up from HK$0.006 in 1H 2024). Revenue: HK$2.06b (down 2.8% from 1H 2024). Net income: HK$14.1m (up 112% from 1H 2024). Profit margin: 0.7% (up from 0.3% in 1H 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Consumer Services industry in Hong Kong. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance. Announcement • Nov 28
EC Healthcare Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended 30 September 2024, Payable on 24 January 2025 EC Healthcare declared Ordinary interim (semi-annual) dividend for the six months ended 30 September 2024 of HKD 0.01 per share. The dividend will be payable on 24 January 2025 with record date of 07 January 2025 and Ex-dividend date of 30 December 2024. New Risk • Nov 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$746.7m (US$96.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Announcement • Nov 09
EC Healthcare to Report First Half, 2025 Results on Nov 28, 2024 EC Healthcare announced that they will report first half, 2025 results on Nov 28, 2024 Announcement • Nov 08
Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024 EC Healthcare provided sales expectations for Six months ended 30 September 2024. For the six months, The Group expects to record overall Sales Volume of no less than HKD 2,100 million for the Period, representing a decrease of no more than 4% as compared with the same period last year. Price Target Changed • Oct 24
Price target increased by 35% to HK$2.84 Up from HK$2.10, the current price target is an average from 3 analysts. New target price is 264% above last closing price of HK$0.78. Stock is down 68% over the past year. The company is forecast to post earnings per share of HK$0.01 next year compared to a net loss per share of HK$0.016 last year. Board Change • Oct 09
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Tsun Au was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Aug 16
EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024 EC Healthcare provided group earnings guidance for the period from 1 April 2024 to 30 June 2024. For the quarter, the company expects overall Sales Volume of no less than HKD 1,040 million for the Quarter, representing a decrease of no more than 4% as compared with the same quarter last year. Reported Earnings • Aug 04
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: HK$0.016 loss per share (down from HK$0.059 profit in FY 2023). Revenue: HK$4.21b (up 8.7% from FY 2023). Net loss: HK$18.9m (down 127% from profit in FY 2023). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Consumer Services industry in Hong Kong. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 28
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: HK$0.016 loss per share (down from HK$0.059 profit in FY 2023). Revenue: HK$4.22b (up 8.9% from FY 2023). Net loss: HK$18.9m (down 127% from profit in FY 2023). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Consumer Services industry in Hong Kong. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance. Announcement • Jun 28
EC Healthcare, Annual General Meeting, Aug 23, 2024 EC Healthcare, Annual General Meeting, Aug 23, 2024. Announcement • Jun 15
EC Healthcare to Report Fiscal Year 2024 Results on Jun 27, 2024 EC Healthcare announced that they will report fiscal year 2024 results on Jun 27, 2024 Announcement • Jun 14
An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million. An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million on June 12, 2024. New Risk • Feb 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (11% average weekly change). Announcement • Dec 08
EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023 The board of directors of EC Healthcare announced that, Mr. Wong Chi Cheung has tendered his resignation as executive director and chief digital officer of the Company with effect from 31 December 2023 due to other work commitments. Mr. Wong has confirmed that he has no disagreement with the Board and there is no other matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the holders of securities of the Company. Price Target Changed • Dec 05
Price target decreased by 15% to HK$5.22 Down from HK$6.13, the current price target is an average from 3 analysts. New target price is 179% above last closing price of HK$1.87. Stock is down 71% over the past year. The company is forecast to post earnings per share of HK$0.21 for next year compared to HK$0.059 last year. Reported Earnings • Dec 02
First half 2024 earnings released: EPS: HK$0.006 (vs HK$0.068 in 1H 2023) First half 2024 results: EPS: HK$0.006 (down from HK$0.068 in 1H 2023). Revenue: HK$2.12b (up 12% from 1H 2023). Net income: HK$6.65m (down 92% from 1H 2023). Profit margin: 0.3% (down from 4.2% in 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Consumer Services industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. Announcement • Dec 01
EC Healthcare Declares an Interim Dividend for the Six Months Ended 30 September 2023, Payable on January 19, 2024 EC Healthcare declared an interim dividend of HKD 0.005 per share for the six months ended 30 September 2023. The dividend payable on January 19, 2024 to the shareholders recorded on 05 January 2024 and the Ex-dividend date is 28 December 2023. Announcement • Nov 18
Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023 EC Healthcare provided earnings guidance for the six months ended 30 September 2023. For the period, the company expects a decrease of not more than 80% in profit after tax ("Net Profit") for the Reporting Period as compared with the Net Profit of approximately HKD 105.2 million for the corresponding period ended 30 September 2022. However, if comparing to the second half of financial year ended 31 March 2023, it is expected that the financial results of the Group may record: an increase of not less than 1,000% in Net Profit for the Reporting Period as compared with the Net Profit of approximately HKD 1.8 million for six months ended 31 March 2023. The Board believes that such year-on-year decrease in Net Profit during the Reporting Period was mainly attributable to: the decrease of approximately HKD 43.4 million in subsidies from Hong Kong Government under the Employment Support Scheme; temporary low operation leverage of the newly established service points from the previous financial year ended 31 March 2023; the increase in depreciation and amortization expenses incurred from the organic expansion during the previous financial year ended 31 March 2023; and the increase in interest expenses from bank borrowings of approximately HKD 17.0 million due the increasing interest rate. Announcement • Nov 17
EC Healthcare to Report First Half, 2024 Results on Nov 30, 2023 EC Healthcare announced that they will report first half, 2024 results on Nov 30, 2023 Announcement • Nov 02
EC Healthcare Announces Executive Changes EC Healthcare Announced that Mr. Tang Chi Fai Eddy has resigned as chief executive officer of the Company with effect from 1 November 2023 due to the wish to enable the Company to fully comply with code provision C.2.1 of the Corporate Governance Code of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which states that the roles of chairman and chief executive should be separate and should not be performed by the same individual. Mr. Tang has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation as chief executive officer of the Company that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the holders of securities of the Company. Mr. Tang will continue to be the Chairman of the Board and an executive Director. Mr. Lu Lyn Wade Leslie, an executive director and the co-chief executive officer of the Company, is re-designated as the chief executive officer of the Company with effect from 1 November 2023. Mr. Lu, aged 44, joined the Group in August 2021 and is an executive director and was the co-chief executive officer of the Company. He focuses on Group's high level strategy, systems building, implementation and cultural alignment. Mr. Lu is a seasoned corporate executive with 22 years of management experience across multiple industry verticals. Mr. Lu worked in Sun Hung Kai Real Estate Agency Limited as Deputy Chief Digital Officer. Before that, Mr. Lu was an executive at Cathay Pacific Airways Limited during 2001-2007 & 2008-2020. His roles include General Manager Digital, General Manager Product, managerial positions in airline planning, cargo, flight operations, customer relationship management as well as oversea station at Thailand, Vietnam and United States. Mr. Lu graduated from The Hong Kong University of Science and Technology ("HKUST") with a Bachelor's degree in Civil Engineering in 2001 and a master's degree in Global Finance in 2009 from New York University and HKUST. Mr. Lu has entered into a service agreement with the Company on 23 August 2021 as an executive director and the co-chief executive officer of the Company for a term of 3 years commencing on 23 August 2021. A supplemental agreement has been entered into between Mr. Lu and the Company on 1 November 2023, pursuant to which Mr. Lu is re-designated as chief executive officer of the Company. Pursuant to the service agreement (as amended), the remuneration of Mr. Lu shall remain unchanged at HKD 400,000 per month plus other discretionary bonus and share options as may be determined by the Board and other terms of appointment shall also remain unchanged. His remuneration package is determined by the Board based on the recommendation of the remuneration committee of the Company, taking into account the salaries paid by comparable companies, time commitment, duties and responsibilities of Mr. Lu, the Company's performance and profitability, the remuneration policy and prevailing market rate. As at the date of this announcement, Mr. Lu holds 10,000,000 share options in the Company. Announcement • Sep 02
Ec Healthcare Approves Dividend for the Year Ended 31 March 2023, Payment Date Is 18 September 2023 EC Healthcare on 23 August 2023 approved dividend of HKD 0.042 per share for the year ended 31 March 2023. Record date is 05 September 2023. Payment date is 18 September 2023. Ex-dividend date is 04 September 2023. Upcoming Dividend • Aug 25
Upcoming dividend of HK$0.042 per share at 2.6% yield Eligible shareholders must have bought the stock before 01 September 2023. Payment date: 18 September 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Hong Kong dividend payers (7.8%). Lower than average of industry peers (4.5%). Announcement • Aug 24
Ec Healthcare Approves Final Dividend for the Year Ended 31 March 2023 EC Healthcare at its annual general meeting held on 23 August 2023 approved final dividend of HKD 0.042 per share for the year ended 31 March 2023. New Risk • Jul 27
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 29% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.8% net profit margin). Reported Earnings • Jul 27
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: HK$0.059 (down from HK$0.17 in FY 2022). Revenue: HK$3.88b (up 33% from FY 2022). Net income: HK$69.7m (down 65% from FY 2022). Profit margin: 1.8% (down from 6.8% in FY 2022). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 66%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Consumer Services industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Major Estimate Revision • Jun 30
Consensus EPS estimates fall by 31% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from HK$0.304 to HK$0.211 per share. Revenue forecast steady at HK$4.83b. Net income forecast to grow 263% next year vs 29% growth forecast for Consumer Services industry in Hong Kong. Consensus price target down from HK$8.99 to HK$7.51. Share price fell 3.2% to HK$4.17 over the past week. Price Target Changed • Jun 26
Price target decreased by 11% to HK$8.03 Down from HK$8.99, the current price target is an average from 8 analysts. New target price is 90% above last closing price of HK$4.22. Stock is down 47% over the past year. The company is forecast to post earnings per share of HK$0.24 for next year compared to HK$0.059 last year. Reported Earnings • Jun 25
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: HK$0.059 (down from HK$0.17 in FY 2022). Revenue: HK$3.95b (up 35% from FY 2022). Net income: HK$69.7m (down 65% from FY 2022). Profit margin: 1.8% (down from 6.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 66%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Consumer Services industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Jun 20
EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023 EC Healthcare provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, company expects a decrease of not more than 61% in profit after tax, a decrease of not more than 20% in EBITDA. Announcement • Jun 13
EC Healthcare to Report Fiscal Year 2023 Final Results on Jun 23, 2023 EC Healthcare announced that they will report fiscal year 2023 final results on Jun 23, 2023 Price Target Changed • Jan 10
Price target increased to HK$9.33 Up from HK$7.93, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of HK$9.21. Stock is down 11% over the past year. The company is forecast to post earnings per share of HK$0.19 for next year compared to HK$0.17 last year. Price Target Changed • Jan 06
Price target increased to HK$8.04 Up from HK$7.51, the current price target is an average from 6 analysts. New target price is 9.4% below last closing price of HK$8.88. Stock is down 8.9% over the past year. The company is forecast to post earnings per share of HK$0.18 for next year compared to HK$0.17 last year. Upcoming Dividend • Dec 21
Upcoming dividend of HK$0.058 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 20 January 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 1.4%. Lower than top quartile of Hong Kong dividend payers (8.6%). Lower than average of industry peers (3.8%). Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improved over the past week After last week's 29% share price gain to HK$6.16, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 6x in the Consumer Services industry in Hong Kong. Total returns to shareholders of 24% over the past three years. Major Estimate Revision • Dec 01
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 EPS estimate fell from HK$0.26 to HK$0.18 per share. Revenue forecast steady at HK$3.72b. Net income forecast to grow 154% next year vs 32% growth forecast for Consumer Services industry in Hong Kong. Consensus price target down from HK$8.89 to HK$7.51. Share price rose 3.3% to HK$5.38 over the past week. Reported Earnings • Nov 25
First half 2023 earnings released First half 2023 results: Net income: HK$80.0m (down 50% from 1H 2022). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Consumer Services industry in Hong Kong. Price Target Changed • Nov 16
Price target decreased to HK$8.89 Down from HK$10.97, the current price target is an average from 4 analysts. New target price is 54% above last closing price of HK$5.78. Stock is down 53% over the past year. The company is forecast to post earnings per share of HK$0.26 for next year compared to HK$0.17 last year. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Tsun Au was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 19% share price gain to HK$4.86, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 6x in the Consumer Services industry in Hong Kong. Total loss to shareholders of 8.5% over the past three years. Price Target Changed • Oct 19
Price target decreased to HK$10.17 Down from HK$11.53, the current price target is an average from 4 analysts. New target price is 131% above last closing price of HK$4.41. Stock is down 61% over the past year. The company is forecast to post earnings per share of HK$0.29 for next year compared to HK$0.17 last year. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorated over the past week After last week's 19% share price decline to HK$4.24, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 5x in the Consumer Services industry in Hong Kong. Total loss to shareholders of 23% over the past three years. Recent Insider Transactions • Sep 04
Chairman & Co-CEO recently bought HK$587k worth of stock On the 1st of September, Chi Fai Tang bought around 107k shares on-market at roughly HK$5.49 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Chi Fai has been a buyer over the last 12 months, purchasing a net total of HK$18m worth in shares. Upcoming Dividend • Aug 29
Upcoming dividend of HK$0.042 per share Eligible shareholders must have bought the stock before 05 September 2022. Payment date: 20 September 2022. Payout ratio and cash payout ratio are on the higher end at 84% and 78% respectively. Trailing yield: 2.6%. Lower than top quartile of Hong Kong dividend payers (8.2%). Lower than average of industry peers (5.0%). Reported Earnings • Jul 28
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: HK$0.17. Revenue: HK$2.92b (up 40% from FY 2021). Net income: HK$197.5m (up 2.4% from FY 2021). Profit margin: 6.8% (down from 9.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 44%. Over the next year, revenue is forecast to grow 26%, compared to a 11% growth forecast for the industry in Hong Kong. Reported Earnings • Jun 24
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: HK$0.17. Revenue: HK$2.97b (up 43% from FY 2021). Net income: HK$197.5m (up 2.4% from FY 2021). Profit margin: 6.7% (down from 9.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 44%. Over the next year, revenue is forecast to grow 27%, compared to a 8.4% growth forecast for the industry in Hong Kong. Price Target Changed • Apr 27
Price target decreased to HK$14.00 Down from HK$15.76, the current price target is an average from 7 analysts. New target price is 74% above last closing price of HK$8.03. Stock is down 14% over the past year. The company is forecast to post earnings per share of HK$0.30 for next year compared to HK$0.19 last year. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Josekin Lam was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.